Switch theme
Sign up to access all valuation multiples
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
2014
32K+
LTM Revenue $14.4B
LTM EBITDA $4.4B
$23.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Viatris has a last 12-month revenue (LTM) of $14.4B and a last 12-month EBITDA of $4.4B.
In the most recent fiscal year, Viatris achieved revenue of $14.7B and an EBITDA of $2.8B.
Viatris expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Viatris valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.4B | XXX | $14.7B | XXX | XXX | XXX |
| Gross Profit | $8.2B | XXX | $5.6B | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | $4.4B | XXX | $2.8B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $4.0B | XXX | $389M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $3.0B | XXX | -$634M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | -4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $13.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Viatris's stock price is $9.
Viatris has current market cap of $10.3B, and EV of $23.8B.
See Viatris trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.8B | $10.3B | XXX | XXX | XXX | XXX | $2.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Viatris has market cap of $10.3B and EV of $23.8B.
Viatris's trades at 1.6x EV/Revenue multiple, and 8.4x EV/EBITDA.
Equity research analysts estimate Viatris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Viatris has a P/E ratio of 3.5x.
See valuation multiples for Viatris and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.3B | XXX | $10.3B | XXX | XXX | XXX |
| EV (current) | $23.8B | XXX | $23.8B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 5.4x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | 5.9x | XXX | 61.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 3.5x | XXX | -16.2x | XXX | XXX | XXX |
| EV/FCF | 12.1x | XXX | 12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialViatris's last 12 month revenue growth is -3%
Viatris's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Viatris's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Viatris's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Viatris and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -3% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Viatris acquired XXX companies to date.
Last acquisition by Viatris was XXXXXXXX, XXXXX XXXXX XXXXXX . Viatris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Viatris founded? | Viatris was founded in 2014. |
| Where is Viatris headquartered? | Viatris is headquartered in United States of America. |
| How many employees does Viatris have? | As of today, Viatris has 32K+ employees. |
| Who is the CEO of Viatris? | Viatris's CEO is Mr. Scott A. Smith. |
| Is Viatris publicy listed? | Yes, Viatris is a public company listed on NAS. |
| What is the stock symbol of Viatris? | Viatris trades under VTRS ticker. |
| When did Viatris go public? | Viatris went public in 1986. |
| Who are competitors of Viatris? | Similar companies to Viatris include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Viatris? | Viatris's current market cap is $10.3B |
| What is the current revenue of Viatris? | Viatris's last 12 months revenue is $14.4B. |
| What is the current revenue growth of Viatris? | Viatris revenue growth (NTM/LTM) is -3%. |
| What is the current EV/Revenue multiple of Viatris? | Current revenue multiple of Viatris is 1.7x. |
| Is Viatris profitable? | Yes, Viatris is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Viatris? | Viatris's last 12 months EBITDA is $4.4B. |
| What is Viatris's EBITDA margin? | Viatris's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Viatris? | Current EBITDA multiple of Viatris is 5.4x. |
| What is the current FCF of Viatris? | Viatris's last 12 months FCF is $2.0B. |
| What is Viatris's FCF margin? | Viatris's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Viatris? | Current FCF multiple of Viatris is 12.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
